Clinical trial
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With…
NCT00231894 · Nathan Kline Institute for Psychiatric Research, Other · Completed
Key facts
| NCT number | NCT00231894 |
|---|---|
| Title | Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia |
| Official title | Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function |
| Lead sponsor | Nathan Kline Institute for Psychiatric Research, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment |
| Intervention type | Behavioral, Drug, Other |
| Interventions | Pioglitazone, Life style diet group, Placebo |
| Enrollment | 56 |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Oct 4, 2005 |
| Last update posted | Dec 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: